Correspondence 0001193125-23-279783 from SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC.
Date: Nov. 17, 2023 · CIK: 0001382101 · Accession: 0001193125-23-279783
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275525
Letter
SUTRO BIOPHARMA, INC.
111 Oyster Point Blvd.
South San Francisco, CA 94080
November 17, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention:
Office of Life Sciences
Re:
Sutro Biopharma, Inc.
Registration Statement on Form S-3
Filed November 13, 2023
File No. 333-275525
Requested Date: November 21, 2023
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Sutro Biopharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553 or, in her absence, to Mr. Mitteness at (206) 389-4533.
* * *
Sincerely,
SUTRO BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP SUTRO BIOPHARMA, INC. 111 Oyster Point Blvd. South San Francisco, CA 94080 November 17, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275525 Requested Date: November 21, 2023 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Sutro Biopharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553 or, in her absence, to Mr. Mitteness at (206) 389-4533. * * * Sincerely, SUTRO BIOPHARMA, INC. By: /s/ Edward C. Albini Edward C. Albini Chief Financial Officer cc: William J. Newell, Chief Executive Officer Sutro Biopharma, Inc. Amanda Rose, Esq. Ryan Mitteness, Esq. Fenwick & West LLP [Signature Page to Company Acceleration Request Letter]